X0609 4 2026-03-20 0001815442 Kymera Therapeutics, Inc. KYMR 0001744425 Esposito Pamela C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 true false false false true Common Stock 2026-03-20 4 M false 2500 49.1 A 2500 D Common Stock 2026-03-20 4 S false 700 77.7111 D 1800 D Common Stock 2026-03-20 4 S false 600 79.2439 D 1200 D Common Stock 2026-03-20 4 S false 1200 79.9442 D 0 D Stock Option (Right to Buy) 49.10 2026-03-20 4 M false 2500 0 D 2031-06-15 Common Stock 2500 0 D These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.46 to $77.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.70 to $79.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.73 to $80.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The shares underlying this stock option are fully vested and exercisable. /s/ Bruce Jacobs, as Attorney-in-Fact 2026-03-20